Inbiomotion

Inbiomotion is a private, commercial-stage diagnostics company based in Barcelona, Spain, founded in 2010. Its core asset is the MAF Test®, a prognostic and predictive biomarker test that analyzes MAF gene expression to guide the use of adjuvant bisphosphonates in early breast cancer. The test, which has been included in Spanish clinical guidelines, aims to improve patient selection, prevent ineffective treatment, and reduce the risk of relapse and bone metastasis. The company is addressing a significant unmet need in a large global market but faces risks related to market adoption, reimbursement, and competition.

Proprietary biomarker platform centered on the analysis of MAF (Musculoaponeurotic Fibrosarcoma) gene expression levels from tumor tissue. The platform identifies patients as MAF-negative (normal expression) or MAF-positive (overexpression) to predict response to adjuvant bisphosphonate therapy in early breast cancer.

Inbiomotion competes in the breast cancer diagnostics market, which includes established multi-gene prognostic assays like Exact Sciences' Oncotype DX and Agendia's MammaPrint. Its differentiation is its specific predictive utility for bisphosphonate therapy response, a niche not directly addressed by broader prognostic tests. It may also face competition from other emerging single-biomarker tests and laboratory-developed tests.